TY - JOUR
T1 - Vascular cognitive impairment
AU - Van Der Flier, Wiesje M.
AU - Skoog, Ingmar
AU - Schneider, Julie A.
AU - Pantoni, Leonardo
AU - Mok, Vincent
AU - Chen, Christopher L.H.
AU - Scheltens, Philip
PY - 2018/2/15
Y1 - 2018/2/15
N2 - The term vascular cognitive impairment (VCI) was introduced around the start of the new millennium and refers to the contribution of vascular pathology to any severity of cognitive impairment, ranging from subjective cognitive decline and mild cognitive impairment to dementia. Although vascular pathology is common in elderly individuals with cognitive decline, pure vascular dementia (that is, dementia caused solely by vascular pathology) is uncommon. Indeed, most patients with vascular dementia also have other types of pathology, the most common of which is Alzheimer disease (specifically, the diffuse accumulation of amyloid-β plaques and neurofibrillary tangles composed of tau). At present, the main treatment for VCI is prevention by treating vascular diseases and other risk factors for VCI, such as hypertension and diabetes mellitus. Despite the current paucity of disease-modifying pharmacological treatments, we foresee that eventually, we might be able to target specific brain diseases to prevent cognitive decline and dementia.
AB - The term vascular cognitive impairment (VCI) was introduced around the start of the new millennium and refers to the contribution of vascular pathology to any severity of cognitive impairment, ranging from subjective cognitive decline and mild cognitive impairment to dementia. Although vascular pathology is common in elderly individuals with cognitive decline, pure vascular dementia (that is, dementia caused solely by vascular pathology) is uncommon. Indeed, most patients with vascular dementia also have other types of pathology, the most common of which is Alzheimer disease (specifically, the diffuse accumulation of amyloid-β plaques and neurofibrillary tangles composed of tau). At present, the main treatment for VCI is prevention by treating vascular diseases and other risk factors for VCI, such as hypertension and diabetes mellitus. Despite the current paucity of disease-modifying pharmacological treatments, we foresee that eventually, we might be able to target specific brain diseases to prevent cognitive decline and dementia.
UR - http://www.scopus.com/inward/record.url?scp=85042226113&partnerID=8YFLogxK
U2 - 10.1038/nrdp.2018.3
DO - 10.1038/nrdp.2018.3
M3 - Article
C2 - 29446769
AN - SCOPUS:85042226113
VL - 4
JO - NATURE REVIEWS DISEASE PRIMERS
JF - NATURE REVIEWS DISEASE PRIMERS
SN - 2056-676X
M1 - 18003
ER -